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ABSTRACT
Objective: In visceral obesity, an overactive endocannabinoid/CB1 receptor (CB1R) system promotes increased caloric intake and decreases
energy expenditure, which are mitigated by global or peripheral CB1R blockade. In mice with diet-induced obesity (DIO), inhibition of food intake
by the peripherally restricted CB1R antagonist JD5037 could be attributed to endogenous leptin due to the rapid reversal of hyperleptinemia that
maintains leptin resistance, but the signaling pathway engaged by leptin has remained to be determined.
Methods: We analyzed the hypothalamic circuitry targeted by leptin following chronic treatment of DIO mice with JD5037.
Results: Leptin treatment or an increase in endogenous leptin following fasting/refeeding induced STAT3 phosphorylation in neurons in the
arcuate nucleus (ARC) in lean and JD5037-treated DIO mice, but not in vehicle-treated DIO animals. Co-localization of pSTAT3 in leptin-treated
mice was signiﬁcantly less common with NPYþ than with POMCþ ARC neurons. The hypophagic effect of JD5037 was absent in melanocortin-4
receptor (MC4R) deﬁcient obese mice or DIO mice treated with a MC4R antagonist, but was maintained in NPY/ mice kept on a high-fat diet.
Conclusions: Peripheral CB1R blockade in DIO restores sensitivity to endogenous leptin, which elicits hypophagia via the re-activation of
melanocortin signaling in the ARC.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
Visceral obesity and its metabolic complications, commonly called the
metabolic syndrome, represent a growing public health concern
worldwide [1]. Accumulating evidence supports the pathogenic role of
an overactive endocannabinoid/CB1 receptor (CB1R) system in obesity/
metabolic syndrome [2e4]. Indeed, the CB1R antagonist/inverse
agonist rimonabant was effective in reducing body weight in obese/
overweight people and also improved the associated insulin resis-
tance, fatty liver, and dyslipidemia [5], but the therapeutic development
of this class of compounds was halted due to neuropsychiatric side
effects mediated by blockade of CB1R in the central nervous system
[6]. More recent evidence indicates that activation of CB1R in periph-
eral tissues, including adipose tissue [7], liver [8], skeletal muscle [9],
the endocrine pancreas [10], and proinﬂammatory macrophages [11],
contributes to visceral adiposity and its metabolic complications, and
its selective blockade by CB1R antagonists/inverse agonists with
limited brain penetrance can improve the obese phenotype in animal
models of diet-induced metabolic syndrome without eliciting behaviors
attributable to blockade of CB1R in the CNS [11e13].
In a previous study, we reported that the peripherally restricted CB1R
inverse agonist JD5037 was as effective as its brain penetrant parent
compound SLV319 (ibipinabant) in normalizing all of the metabolic
consequences of a high-fat diet (HFD), including the normalization of
body weight as well as causing transient but pronounced hypophagia
[13]. The latter effect was surprising in view of the dominant role of
central neural circuits in the control of food intake. To resolve this
paradox, we posited that the hypophagic effect of chronic blockade of
peripheral CB1R is mediated by endogenous leptin, as a result of the
rapid reversal of the hyperleptinemia and associated leptin resistance
of diet-induced obese (DIO) mice [13]. Reversal of the hyperleptinemia,
in turn, could be attributed to reduced leptin production due to direct
inhibition of CB1R in adipocytes and sympathetic nerve endings in
adipose tissue, as well as increased leptin clearance in the kidney, due
to inhibition of CB1R in renal proximal tubular cells [13].
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The ability of peripherally generated leptin to reach its hypothalamic
receptors reconciles the paradox of modulating a centrally regulated
function using a drug restricted to the periphery. The question remains:
which neural circuits are activated by endogenous leptin, once the
leptin resistance in DIO mice is reversed by treatment with a periph-
erally restricted CB1R inverse agonist. Generally, leptin coordinates the
activity of the appetitive neural circuitry primarily via promoting the
activity of pro-opiomelanocortin (POMC)/cocaine- and amphetamine-
regulated transcript (CART) neurons [14e16] and subsequent
anorexigenic signaling by a-melanocyte-stimulating hormone (a-MSH)
via the melanocortin 4 receptor (MC4R) [17] and simultaneously
inhibiting the activity of orexigenic neuropeptide Y (NPY)/agouti-related
peptide (AgRP) neurons in the arcuate nucleus (ARC) [18,19]. There-
fore, we examined the relative role of these two pathways in the
anorexigenic effect of endogenous leptin in DIO mice chronically
treated with the peripheral CB1R antagonist JD5037. The results
indicate that resensitization of DIO mice to leptin is reﬂected in
increased leptin-induce phosphorylation of STAT3 in both POMC and
NPY neurons, with the former playing a key role in the anorexigenic
and weight reducing actions of endogenous leptin, as reﬂected in the
absence of these effects in MC4R knockout mice or DIO mice treated
with an MC4R antagonist.
2. MATERIALS AND METHODS
2.1. Animals and experimental protocol
The experimental protocol was approved by the Institutional Animal
Care and Use Committees of the NIAAA and Hebrew University of
Jerusalem. Male 6-week old NPY/ mice (129S-Npytm1Rpa/J) and
their littermate controls were obtained from the Jackson Laboratory.
Adult, male, genetically obese MC4R/ mice (MC4Rtm1Lowl/J) were
generated by heterozygote mating using wild-type littermates as
controls. Mice were maintained under a 12 h light/dark cycle and fed
ad libitum. To generate DIO, C57Bl6/J and NPY/ mice were fed a
HFD (Research Diet, D12492; 60% calories from fat, 20% from protein,
and 20% from carbohydrates), with age-matched lean controls
receiving a standard laboratory diet (STD, NIH-31 rodent diet) for 12e
14 weeks. To achieve normoleptinemia in DIO mice, we adapted a
protocol described by Knight et al. [20]. Brieﬂy, leptin-deﬁcient ob/ob
mice were implanted with an osmotic minipump (model 2001D, Alzet
Osmotic Pumps; Durect, Cupertino, CA) delivering leptin dissolved in
phosphate-buffered saline (PBS) at a rate of 150 ng/h for 12 weeks,
during which time they were fed a HFD to induce DIO. Control groups of
wild-type mice on HFD and ob/ob mice on STD were also implanted
with minipumps delivering PBS at the same rate. Pumps were replaced
every 28 days. HFD-induced obese C57Bl/6J, NPY/ and normo-
leptinemic ob/ob mice, and genetically obese MC4R/ mice on STD
were treated daily with JD5037 (3 mg/kg/day, po) or vehicle (Veh; 4%
DMSO þ 1% Tween80 in normal saline) for 7 days. Body weight and
food intake were monitored daily. Mice were euthanized by cervical
dislocation under anesthesia, and their brains and trunk blood were
collected for further analyses.
2.2. Leptin sensitivity
Leptin sensitivity was assessed in lean and DIO mice and DIO mice
treated daily with JD5037 (3 mg/kg po.) for 7 days followed by twice
daily treatment with leptin (3 mg/kg, ip) or vehicle for an additional 4
days. One hour after the last dose of leptin or vehicle, mice were
anesthetized, perfused via the left ventricle with 5 mL of 0.9% saline
for 1 min followed by 60e80 mL of cold 0.1 M phosphate buffer (pH
7.4) containing 4% paraformaldehyde for 15 min at room temperature.
Then, the perfused brains were removed, post-ﬁxed in the same
ﬁxative for 6 h at 4 C and further processed for immunohistochemical
analyses.
2.3. Immunohistochemistry
After ﬁxation, the brains were cryoprotected with 0.1 M phosphate
buffer (pH 7.4) containing 20% sucrose for 72 h and then rapidly frozen
in isopentane pre-cooled to70 C with dry ice. Serial coronal sections
(30 mm) were cut using a cryostat through the brain region containing
the ARC. After inactivating the endogenous peroxidase activity with
0.6% hydrogen peroxidase (SigmaeAldrich, St. Louis, MO), sections
were incubated separately with avidin and biotin solutions (Vector Lab,
Burlingame, CA) for blocking nonspeciﬁc binding of endogenous biotin,
biotin-binding protein, and lectins. Then, the sections were incubated
free-ﬂoating in 0.01 M PBS (pH 7.4) containing 2% normal donkey
serum (Jackson ImmunoResearch Labs, West Grove, PA), 0.3% Triton
X-100 (SigmaeAldrich, St. Louis, MO) and rabbit anti-pSTAT3 antibody
(1:1,500; Cell Signaling, Beverly, MA) or rabbit anti-c-Fos antibody
(1:10,000; Santa Cruz Biotechnology, CA) for 43 h at 4 C. The
immunoreaction product was visualized using the Vectastain elite ABC
kit (Vector Lab., Burlingame, CA) and 30,30-diaminobenzidine (Sigmae
Aldrich, St. Louis, MO) as a chromogen. After thorough washes, sec-
tions were mounted on gelatin-coated slides. Following dehydration in
ethanol, sections were cleared in xylene and coverslipped in
Permount (Fisher Scientiﬁc, Fair Lawn, NJ). Staining for pSTAT3 and
c-Fos were visualized using a bright ﬁeld light source and captured with
a digital camera mounted on an Olympus BX41 microscope.
Sections earmarked for double labeling with pSTAT3þPOMC or
pSTAT3þNPY were processed according to the indirect immunoﬂuo-
rescence method of Coons [21]. Brieﬂy, following washes in PBS, the
sections were incubated free-ﬂoating in PBS containing Triton X-100,
blocking serums and two primary antibodies: rabbit anti-pSTAT3
(1:500; Cell Signaling, Beverly, CA) and chicken anti-POMC (1:1,000;
Abcam, Cambridge, MA) or rabbit anti-pSTAT3 (1:500; Cell Signaling)
and chicken anti-NPY (1:2,000; Novus Biologicals) for 43 h at 4 C.
Then, the sections were incubated at room temperature in PBS con-
taining Triton X-100, blocking serum, and donkey anti-Rabbit Alexa
Fluor 594 (1:250; Invitrogen) for 1 h, and then Triton X-100, blocking
serum, and goat anti-chicken Alexa Fluor 488 (1:250; Invitrogen) for
another hour. After thorough washes in PBS, all sections were mounted
on gelatin-coated microscope slides, coverslipped with Vectashield
(Vector Lab.), and analyzed using a Zeiss LSM700 confocal microscope.
The localization of the immunoreactive signals was identiﬁed using
Hof’s mouse brain atlas. Six corresponding sections in the ARC,
organized in a consecutive rostral to caudal sequence from0.94 mm
to 2.92 mm relative to the bregma, were counted for pSTAT3 and c-
Fos positive cells and analyzed for co-localization of pSTAST3 with
POMC or NPY positive cells. Cell counts from 4 mice per group were
obtained from both sides of the brain in each section. pSTAT3-, c-Fos-,
POMC-, and NPY-positive cells as well as double labeled cells were
scored in each ARC section from vehicle and leptin-treated animals.
The percentage of double-positive pSTAT3þ POMC or pSTAT3þ NPY
cells was also determined by cell counting.
2.4. Blood biochemistry
Serum leptin levels were measured by an ELISA kit (Millipore, Billerica,
MA, and R&D Systems, Minneapolis, MN).
2.5. Chronic infusion of SHU-9119
To assess whether hypothalamic MC4R mediates the response to
peripheral CB1R antagonism in DIO mice, vehicle (saline) or the MC4R
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antagonist SHU-9119 (Tocris; 24 nmol/day) was delivered over 7 days
by intracerebroventricular (icv) infusion using osmotic minipumps. The
effects of simultaneous 7-day treatment with daily oral doses of vehicle
or JD5037 (3 mg/kg, po.) on body weight, food intake, and serum
leptin levels were determined as described above.
2.6. Fasting/refeeding paradigm
To determine whether peripheral CB1R blockade resensitizes endog-
enous leptin action, we used a fasting/refeeding paradigm. Brieﬂy,
male, 6e7 week old C57Bl/6J mice were kept on STD or HFD for 5
weeks. During the last week of feeding, the mice were treated with
either vehicle or JD5037 (3 mg/kg, po.) for 1 week. Following the last
dose, the mice were fasted for 16 h and then food was introduced for
an additional 4 h before sacriﬁce. The hypothalamus and trunk blood
were collected from each mouse, and the phosphorylation of STAT3
was determined by western blotting, while serum leptin levels were
measured by an ELISA kit (Millipore, Billerica, MA).
2.7. Endocannabinoid measurements
Mice were euthanized and the brain and hypothalamus were rapidly
dissected and kept at 80 C until processed. Arachidonoyl ethano-
lamide (AEA) and 2-arachidonoylglycerol (2-AG) in brain cortex and
hypothalamus were extracted, puriﬁed, and quantiﬁed by the stable
isotope dilution LC-MS/MS method described previously [13].
2.8. Materials
Rimonabant was obtained from the National Institute of Drug Abuse
Drug Supply Program. JD5037, kindly provided by Jenrin Discovery,
Inc. [22]. For oral administration by gavage, rimonabant and JD5037
were dissolved in 4% DMSOþ 1% Tween-80 in saline. SHU-9119 was
purchased from Tocris and was dissolved in saline to be administered
by an Alzet osmotic minipump (Durect, Cupertino, CA) at the rate of
24 nmol/day as described previously [23,24].
2.9. Statistics
Data are expressed as mean  SEM. Unpaired two-tailed Student’s t-
test was used to determine differences between vehicle- and drug-
treated groups. Results in multiple groups were compared by one-
or two-way ANOVA followed by a Bonferroni or Sidak’s multiple
comparisons test, as appropriate (GraphPad Prism v6 for Windows).
Signiﬁcance was set at P < 0.05.
3. RESULTS
3.1. Hyperleptinemia is required for the hypophagic and weight
reducing effects of peripheral CB1R blockade
We have previously demonstrated that the weight reducing and
hypophagic effects of JD5037 in DIO mice develop rapidly within 7
days of treatment and are associated with a similar rapid reversal of
hyperleptinemia and leptin resistance [13]. Here we sought to further
test whether hyperleptinemia is, in fact, a prerequisite of the efﬁcacy of
peripheral CB1R blockade. To this end, we tested the effects of JD5037
in obese mice with substantially different leptin status using an
approach based on that developed by Knight et al. [20], as detailed in
the Methods section and illustrated in Figure 1A and B.
Treatment with a daily oral dose of JD5037 (3 mg/kg) for 14 days failed
to signiﬁcantly affect body weight, food intake, and plasma leptin levels
in obese but normoleptinemic animals (ob/ob mice on HFD chronically
infused with leptin) and was similarly ineffective in aleptinemic ob/ob
mice. On the other hand, and in accordance with our previous ﬁndings
[13], JD5037 treatment alleviated hyperleptinemia, caused transient
Figure 1: Effects of peripheral CB1R blockade on food intake and body weight in
obese mice with different leptin status. (A) Experimental protocol yielding obese
mice with aleptinemia (ob/ob mice on standard diet [STD] and chronically infused with
PBS), normoleptinemia (ob/ob mice on high-fat diet [HFD] infused with leptin), or
hyperleptinemia (wild-type mice on HFD, infused with PBS). Horizontal line indicates the
period of leptin or PBS infusion. (B) Mean body weights at the end of the pretreatment
period. n ¼ 10, 13, and 11 for ob/ob STD, ob/ob HFD þ leptin and WT HFD þ PBS
groups, respectively. *P < 0.0001 as compared to ob/ob STD þ PBS group. (C) Daily
food intake and body weight of vehicle-treated (open symbols) and JD5037-treated
animals (ﬁlled symbols), n ¼ 6 in all 6 groups. #P < 0.001 for the effect of JD5037
vs vehicle treatment. (D) Serum leptin concentrations on day 14 of JD5037 or vehicle
treatment, n ¼ 4e6 mice per group. Leptin was undetectable in sera of ob/ob mice
infused with PBS. #P < 0.0001 relative to vehicle-treated WT mice.
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hypophagia, and signiﬁcantly reduced body weight in wild-type DIO
mice (Figure 1C and D). Furthermore, the weight-reducing effect of
JD5037 in the last group could be counteracted by daily treatment with
a pharmacologic dose of leptin which also reversed the JD5037-
induced decrease in plasma leptin (Supplementary Fig. 1). Together,
these ﬁndings support the notion that the anorectic and weight
reducing effects of peripheral CB1R blockade in DIO are contingent on
hyperleptinemia and its drug-induced reversal.
3.2. Peripheral CB1R blockade restores hypothalamic leptin
sensitivity
Next, we analyzed leptin-induced STAT3 phosphorylation in the
diencephalon, a marker of leptin signaling, to test whether peripheral
CB1R blockade restores leptin sensitivity in the mediobasal hypothal-
amus. As illustrated in Figure 2A, B, leptin treatment robustly increased
STAT3 phosphorylation in the ARC of lean control mice with a few
responsive cells also present in the adjacent ventromedial hypothal-
amus (VMH). Although the number of pSTAT3þ cells in the VMH was
increased in vehicle-treated DIO mice compared to lean control mice,
leptin treatment was without any effect on hypothalamic pSTAT3 in DIO
mice, similar to ﬁndings by others [20,25]. In contrast, in DIO mice
treated with JD5037 for 7 days, leptin treatment robustly increased
STAT3 phosphorylation, similarly to its effect in lean controls. To
determine the effects of leptin treatment, HFD status and peripheral
CB1R blockade on neuronal activity in the ARC, we examined the
expression of c-Fos protein in consecutive brain sections used to
evaluate pSTAT3 expression. We found that the leptin-induced in-
crease in c-Fos expression in the ARC of lean mice was completely
absent in vehicle-treated DIO mice but was partially restored in
JD5037-treated DIO mice (Figure 2C, D). Thus, peripheral CB1R
blockade restores hypothalamic leptin-induced STAT3 phosphorylation
and neural activation in DIO mice.
Figure 2: Peripheral CB1R blockade restores hypothalamic leptin-induced STAT3 phosphorylation in DIO mice. Effect of leptin (3 mg/kg, ip twice daily for 4 days) on
tyrosine705-phosphorylated STAT3-positive (pSTAT3þ) neurons (A) or c-Fos expression (C) in hypothalamic coronal sections obtained from lean and DIO C57Bl/6J mice treated for
7 days with either vehicle or JD5037 (3 mg/kg, po). Quantiﬁcation of the number of pSTAT3þ cells (B) or c-Fosþ cells (D) in the ARC. Data are mean  SEM from 4 animals in
each group. *P < 0.05 relative to the corresponding control group treated with vehicle (Veh).
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Analyses of leptin sensitivity typically involve the use of pharmaco-
logical doses of leptin even in lean mice. We therefore tested whether
changes in the phosphorylation status of STAT3 are also detectable in
response to changes in the plasma levels of endogenous leptin within
its physiological range. Leptin plasma levels drop during fasting and
increase upon refeeding [26]. We therefore tested the effects of
overnight fasting followed by brief refeeding on plasma leptin levels
and pSTAT3/STAT3 status in the mediobasal hypothalamus. As shown
in Figure 3, plasma leptin level at the end of the fasting period was low
in lean mice, was about ten times higher in vehicle-treated DIO mice,
Figure 3: Peripheral CB1R blockade restores sensitivity to endogenous leptin. Wild-type C57Bl/6J mice on STD or HFD were treated orally for one week with 3 mg/kg/day
JD5037 or vehicle. After the last dose the mice were fasted for 16 h, then provided access to food for 4 h, after which they were sacriﬁced and brain tissue and plasma were
collected for quantifying plasma leptin (A), and hypothalamic pSTAT3/STAT3 (B and C), as detailed in Methods. Quantitation of pSTAT3 in panel B was done by densitometry, and
values are expressed as the ratio of pSTAT3/STAT3. Data are mean  SEM from 5 animals in each group. *P < 0.05 relative to the corresponding value in the fasted group.
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Figure 4: Peripheral CB1R blockade increases leptin-induced tyrosine
705-STAT3 phosphorylation in NPY-positive neurons. Representative photomicrographs showing
tyrosine705-pSTAT3þ neurons (red) and NPYþ neurons (green) in the hypothalamic ARC 45 min after the last injection of leptin (3 mg/kg, ip. twice daily for 4 days) or vehicle (A).
Insets (AeF): Examples of NPYþ neurons coexpressing pSTAT3. Quantitation of the percentage of pSTAT3þ NPY neurons in coronal brain sections (B). pSTAT3þ NPY neurons were
counted from four brain sections from each group. *P < 0.05 relative to the corresponding control group treated with Veh. #P < 0.05 relative to the leptin-treated mice in the STD-
Veh group.
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and returned to near control levels in DIO mice treated for one week
with daily doses of 3 mg/kg JD5037. Refeeding elicited signiﬁcant,
several-fold increases in plasma leptin in both lean mice and DIO mice
treated with JD5037, but no signiﬁcant further increase was evident in
vehicle-treated DIO mice. STAT3 phosphorylation quantiﬁed using
Western blots showed parallel changes, being signiﬁcantly increased
upon refeeding in lean and in DIO mice treated with JD5037 but not in
vehicle-treated DIO animals. This indicates that JD5037 treatment of
obese mice reverses their resistance to endogenous leptin.
3.3. Inhibition of NPY signaling by leptin is not involved in the
weight reducing and hypophagic effects of peripheral CB1R blockade
in DIO mice
In the above experiments, JD5037 treatment restored leptin
responsiveness in the ARC of DIO mice and normalized their body
weight. These effects of leptin can be mediated either by inhibition of
orexigenic NPY/AgRP neurons or activation of anorexigenic POMC/
CART neurons in the ARC [27,28]. We ﬁrst explored the possibility that
the restored effects of leptin that result from peripheral CB1R
Figure 5: Peripheral CB1R blockade is equieffective in wild-type and NPY
L/L mice on HFD. (A) Body weight and food-intake of WT and NPY/ mice kept on STD or HFD
and treated with JD-5037 or vehicle. *P < 0.01, JD5037 vs vehicle, n ¼ 5 in all groups except for STD groups (n ¼ 4) and NPY/ HFD JD-5037 treated (n ¼ 4). (B) Serum leptin
concentrations on day 7 of JD5037 treatment. *P < 0.01, vs STD; #P < 0.01 and ###P < 0.001 vs HFD vehicle group. Numbers of observations were as in A.
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Figure 6: Peripheral CB1R blockade increases leptin-induced tyrosine
705-STAT3 phosphorylation in POMC-positive neurons. Representative photomicrographs showing
tyrosine705pSTAT3þ neurons (red) and POMC-positive neurons (green) in the hypothalamic ARC 45 min after the last injection of leptin (3 mg/kg, ip twice daily for 4 days) or vehicle
(A). Insets (AeF): examples of POMCþ neurons co-expressing pSTAT3. Quantitation of the percentage of pSTAT3þ POMC neurons in coronal brain sections (B). pSTAT3þ POMC
neurons were counted from four brain sections from each group. *P < 0.05 relative to the corresponding control group treated with Veh. #P < 0.05 relative to the vehicle þ leptin-
treated mice in the STD-Veh group.
Original Article
8 MOLECULAR METABOLISM- (2017) 1e13  2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
blockade involve the NPY/AgRP pathway. As shown in Figure 4, leptin
induced detectable STAT3 phosphorylation in about one third of NPY-
positive neurons in lean mice, as assessed by double immunohisto-
chemistry and confocal microscopy. HFD suppressed leptin-activated
STAT3 phosphorylation in NPY-positive neurons, and this suppression
was only partially reversed by chronic treatment with JD5037 (3 mg/
kg, po) for 7 days (Figure 4A, B).
To further test the functional role of altered NPY signaling in
mediating the weight reducing and hypophagic effects of JD5037,
we treated HFD-induced obese NPY/ mice and their HFD-fed
wild-type littermates with JD5037 (3 mg/kg, po) for 7 days and
monitored their body weight, food intake, and serum leptin levels.
Compared to wild-type mice on STD, both wild-type and NPY/
mice on HFD displayed similar signiﬁcant increases in body weight
(Figure 5A), visceral adiposity (Supplementary Fig. 2B), and serum
leptin levels (Figure 5B). JD5037 caused robust decreases in body
weight, food intake, and serum leptin levels in NPY/ animals,
which were similar or, in the case of serum leptin, even slightly
greater than its parallel effects in wild-type DIO littermates
(Figure 5A,B, and Supplementary Fig. 2). These ﬁndings argue
against the involvement of NPY in the weight reducing effect of
JD5037, although they do not rule out the possible involvement of
AgRP.
3.4. Peripheral CB1R blockade restores hypothalamic leptin
sensitivity via POMC signaling
Since leptin activates the anorexigenic POMC/CART neurons in the ARC
[14,16], we next explored whether peripheral CB1R blockade affects
this neuronal pathway. Consistent with previous reports [28], leptin
administration stimulated STAT3 phosphorylation in POMC-positive
neurons of lean mice, as assessed by double immunohistochemistry
and confocal microscopy (Figure 6). The percentage of POMCþ/
pSTAT3þ neurons in the ARC (57.4  3.3%) was signiﬁcantly higher
than the percentage of NPYþ/pSTAT3þ neurons (see Figure 4,
35.9  6.8%, P < 0.01). Leptin-stimulated STAT3 phosphorylation in
these neurons was completely abrogated in DIO mice, although basal
pSTAT3 levels were signiﬁcantly increased. Leptin-induced STAT3
phosphorylation was fully restored in DIO mice treated with JD5037
(3 mg/kg, po.) for 7 days (Figure 6) prior to leptin treatment, suggesting
that peripheral CB1R blockade enhances hypothalamic leptin signaling
via the activation of anorexigenic POMC neurons.
The anorexigenic effect of leptin is believed to be mediated by a-MSH
acting on MC4R [29]. To explore the functional role of POMC-positive
neurons in mediating the hypophagic effect of JD5037, we treated
STD-fed obese MC4R/ mice and their HFD-fed littermate controls
with JD5037 (3 mg/kg, po.) for 7 days and monitored their body
weight, food intake, and serum leptin levels. As shown in Figure 7, the
Figure 7: MC4R deactivation abolishes the hypophagic and weight reducing effects of peripheral CB1R blockade. JD5037 (3 mg/kg, po, for 7 days) reduced body weight
(A) and food intake (B) in DIO mice but not in MC4R/ animals. Absolute body weights of DIO mice are: 42.3  0.7 g (Veh) vs 36.4  0.9 g (JD5037), and of MC4R/ mice:
43.2  1.5 (Veh) vs 42.3  1.8 g (JD5037). Serum leptin levels were similarly reduced by JD5037 in both mouse strains, although the net values were much greater in MC4R/
mice (C). Treatment of DIO mice with SHU-9119 (24 nmol/day, icv via osmotic minipump, for 7 days) attenuated the reductions in body weight, food intake and serum leptin levels
induced by JD5037 (3 mg/kg/day, po, for 7 days) (EeG). Absolute body weights in saline-infused DIO mice are 50.0  1.6 g (Veh) vs 41.9  0.8 g (JD5037), and in SHU-9119-
infuced DIO mice are 53.8  0.9 g (Veh) vs 49.5  1.2 g (JD5037). D, representative pictures of a cannulated brain demonstrating the location of the cannula and the injection site
of SHU-9119 into the 3rd ventricle (blue staining). Data are obtained from 4 to 5 animals in each group. *P < 0.05 relative to the corresponding obese group treated with Veh;
#P < 0.05 relative to the corresponding DIO group treated with either Veh or JD5037.
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weight reducing and hypophagic effects of JD5037 observed in DIO
mice were absent in MC4R/ mice (Figure 7A, B). Although JD5037
treatment reduced serum leptin levels in both mouse strains, the
absolute levels remained signiﬁcantly higher in MC4R/ compared to
DIO mice (Figure 7C). To further test the role of MC4R in mediating the
increased hypothalamic signaling of leptin in DIO mice treated with
JD5037, we continuously infused via a minipump the potent MC4R
antagonist, SHU-9119 (24 nmol/day, icv) to HFD-fed animals that were
simultaneously treated with daily oral doses of JD5037 (3 mg/kg) or
vehicle for 7 days. The correct location of the icv infusion of SHU-9119
into the 3rd ventricle was veriﬁed postmortem by the infusion of to-
luidine blue (Figure 7D). In the presence of SHU-9119, the effects of
JD5037 on body weight, food intake, and serum leptin levels were
signiﬁcantly attenuated (Figure 7EeG). Unlike these results, treatment
of MC4R/ mice with the globally acting CB1R inverse agonist
rimonabant resulted in reductions in body weight, food intake and
serum leptin levels (Figure 8AeC).
3.5. Effects of high-fat diet and peripheral CB1R blockade on
hypothalamic endocannabinoids
Our laboratory has earlier documented an inverse relationship between
leptin and hypothalamic endocannabinoids levels and a role in appetite
regulation [30]. We therefore measured the tissue levels of AEA and 2-
AG in the cortex and hypothalami of lean and DIO mice as well as DIO
mice chronically treated with JD5037 (3 mg/kg, po.). As seen in
Supplementary Figure 3, keeping mice on HFD resulted in a signiﬁcant
increase in hypothalamic 2-AG and a smaller, not statistically signiﬁ-
cant increase in AEA levels. In contrast, treatment of DIO mice with
JD5037 signiﬁcantly reduced AEA, but not 2-AG levels. These changes
were speciﬁc for the hypothalamus, as brain endocannabinoid levels
remained unchanged by either diet or drug treatment.
4. DISCUSSION
Rimonabant, the ﬁrst-in-class, globally acting CB1R antagonist/inverse
agonist is an anti-obesity agent that not only reduced body weight but
also improved all the associated metabolic abnormalities [5]. Although
neuropsychiatric side-effects led to its withdrawal from the market,
this was not unexpected in view of the known obligatory role of
endocannabinoids and CB1R in the mesolimbic dopaminergic reward
pathway in mediating both natural and drug reward [31]. Subsequent
evidence that non-brain-penetrant CB1R antagonists are, as or nearly
as, effective as rimonabant in improving metabolic end points could be
attributed to the presence of CB1R at low yet functionally relevant levels
in tissues involved in metabolic control and their upregulation in
obesity. On the other hand, the efﬁcacy of peripheral CB1R blockade in
reducing food intake in DIO mice was surprising in view of the
dominant role of a central neural circuitry in appetite control. The
absence of a similar effect in mice with defective leptin signaling or in
wild-type DIO mice treated with a leptin antagonist supported the
hypothesis that the hypophagic effect of peripheral CB1R blockade is
mediated by endogenous leptin, due to the rapid reversal of hyper-
leptinemia and the associated leptin-resistant state [13]. This notion is
further supported by the present ﬁndings that the ability of peripheral
CB1R blockade to reduce food intake and body weight is abrogated by
clamping serum leptin levels of DIO mice at the normal physiologic
range (Figure 1), or by the infusion of exogenous leptin to counter the
leptin lowering effect of JD5037 in hyperleptinemic DIO mice
(Supplementary Figure 1). These observations are also in agreement
with the concept of Knight et al. [20] that hyperleptinemia is both
necessary and sufﬁcient for maintaining leptin resistance in DIO.
The present ﬁndings further indicate that once the leptin resistance of
DIO mice is reversed by peripheral CB1R blockade, endogenous leptin
acts in the hypothalamus primarily via activating POMC neurons
resulting in MC4R activation, as indicated both by increased STAT3
phosphorylation in POMC neurons and a parallel increase in c-Fos
expression in the ARC. The dominant role of melanocortin signaling is
further supported by the failure of peripheral CB1R blockade to reduce
food intake and body weight in obese MC4R/ mice and its reduced
efﬁcacy in DIO mice simultaneously exposed to a MC4R antagonist. In
contrast, the hypophagic effect of JD5037 is fully maintained, if not
increased, in HFD-fed NPY/ mice compared to their HFD-fed wild-
type littermates, which is similar to the maintained hypophagic effect
of rimonabant in overnight fasted NPY/ mice [30]. The preferential
activation of POMC neurons is also indicated by the signiﬁcantly
greater co-localization of pSTAT3 with POMC than with NPY expressing
arcuate neurons following leptin challenge of JD5037-treated DIO
mice. Nevertheless, the co-expression of pSTAT3 with some NPY
neurons could reﬂect their inhibition by leptin that would result in
reduced AgRP expression and, as a consequence, disinhibition of
melanocortin signaling. This mechanism would be retained in NPY/
mice as gene deletion of NPY does not affect the AgRP content of these
neurons [32].
Refeeding after fasting was associated with a signiﬁcant increase in
serum leptin and a parallel increase in hypothalamic pSTAT3 in lean
and JD5037-treated DIO mice, but not in vehicle-treated DIO mice.
This is compatible with the role of pSTAT3 signaling in the metabolic
effects of endogenous leptin, as proposed previously [33,34]. The HFD-
Figure 8: MC4R deactivation does not abolish the hypophagic effect of global CB1R blockade. Rimonabant (3 mg/kg, po., for 7 days) reduced body weight (A), food intake
(B) and serum leptin levels (C) in MC4R/ mice. Absolute body weights are 52.5  2.9 g (Veh) vs 49.6  2.3 g (rimonabant). Data are mean  SEM from 4 to 5 animals in each
group. *P < 0.05 relative to the corresponding control group treated with Veh.
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induced increase in the baseline level of hypothalamic pSTAT3
(Figure 2) is also compatible with recent evidence that ARC neurons in
DIO mice remain sensitive to endogenous leptin in leptin-resistant
states, elicited by high-fat diets [35,36], or chronic central infusion
of leptin [37]. However, our ﬁndings also indicate that at the high
circulating levels of leptin associated with DIO, leptin receptors are
maximally activated, so that any further increase in leptin either from
endogenous or exogenous sources results in no change in either
pSTAT3 or food intake. The apparent dissociation between functional
leptin resistance and continued leptin signaling in ARC neurons in DIO
may be related to the control of endogenous reactive oxygen species in
the hypothalamus [38].
Although the role of the LepR/pSTAT3/aMSH/MC4R pathway in the
acute metabolic effects of leptin is well established [17,33,39], genetic
inactivation of STAT3 in POMC neurons reduced, but did not abolish,
the hypophagic effect of leptin [40], whereas STAT3 inactivation in
AgRP/NPY neurons also attenuated leptin-induced hypophagia [41].
This suggests that both POMC and AgRP/NPY neurons could be targets
of the acute metabolic effects of leptin. Although STAT3 phosphory-
lation following chronic peripheral CB1R blockade could be detected in
a small proportion NPYþ neurons (Figure 4), genetic deletion of NPY did
not affect the acute metabolic response of DIO mice to leptin (Figure 5).
Nevertheless, these ﬁndings do not rule out the role of the AgRP/NPY
pathway in the hypophagic effects of leptin under different conditions.
Indeed, recent ﬁndings indicate that AgRP neurons drive consumma-
tory feeding but are dispensable for reward-driven feeding of palatable
foods, such as a HFD used in the present study [42].
It was reported that young pre-obese MC4R/ mice retain sensitivity
to exogenous leptin [29] and to leptin receptor antagonist [35],
whereas older animals with manifest obesity do not respond to such
treatments. This implies that there is an age and/or obesity-dependent
switch towards the POMC pathway to convey the central effects of
leptin on energy metabolism [35]. Whether such a shift is predomi-
nantly age or obesity related remains to be determined, but it is
noteworthy that the age-related decrease in central leptin sensitivity
was found to be promoted by concurrent obesity [43]. Nevertheless,
the above ﬁndings are in good agreement with the present observa-
tions that once peripheral CB1R blockade resensitizes the mediobasal
hypothalamus to leptin, the hormone signals primarily via the mela-
nocortin system to reduce food intake and body weight in obese
animals.
Earlier ﬁndings indicate that both peripheral and central CB1R are
involved in the orexigenic effects of endocannabinoids. Peripherally
restricted CB1R antagonists inhibit food intake in HFD-fed mice
[12,13,44] in a leptin-dependent manner [13], but failed to inhibit the
hunger-induced increase in food intake in STD-fed lean mice, which
could still be inhibited by rimonabant in a leptin-independent manner
[13]. Similarly, JD5037 treatment failed to reduce food intake and body
weight in MC4R/ mice, whereas rimonabant retained its efﬁcacy. It
could be argued that intact leptin signaling via MC4R mediates the
hypophagic effect of peripheral CB1R blockade, but not the effect of
rimonabant, which, in these animals, is likely due to blockade of CB1R
in the CNS. Indeed, pharmacological blockade of MC4R was reported
to cause a delayed increase in hypothalamic endocannabinoid levels
[45], and a possible similar increase in the hypothalami of MC4R/
mice may contribute to their hyperphagia via increased CB1R activa-
tion, which would be antagonized by rimonabant.
Paradoxically, altered central CB1R activity may also contribute to the
hypophagic effect of peripheral CB1R blockade. Our laboratory has
earlier reported that leptin-deﬁcient ob/ob mice have elevated 2-AG
levels in the hypothalamus, whereas leptin treatment of these
animals preferentially reduces hypothalamic AEA [30]. Interestingly,
the same pattern was evident in the present study, in which HFD
feeding increased hypothalamic 2-AG (in agreement with the ﬁndings
of others [46,47]), and JD5037 treatment decreased hypothalamic AEA
levels. This is compatible with the hypothesis that the hypophagic
effect of JD5037 is mediated by endogenous leptin [13], in part
through reducing central AEA/CB1R signaling.
Hyperleptinemia is thought to be responsible for maintaining a leptin
resistant state in obesity [20], and we have earlier demonstrated that
peripheral CB1R blockade reverses the hyperleptinemia of DIO mice by
antagonizing leptin production in adipose tissue and promoting leptin
clearance by the kidney [13]. Because circulating leptin can reach the
mediobasal hypothalamus [48], normalization of plasma leptin may
directly lead to resensitization of hypothalamic leptin receptors,
resulting in increased signaling by endogenous leptin. Alternatively,
circulating leptin may regulate the sensitivity of hypothalamic leptin
receptors indirectly, through vagal afferent neurons. Leptin receptors
are expressed in vagal afferents innervating the stomach and duo-
denum, and their activation was reported to promote satiety [49,50],
whereas their genetic deletion led to hyperphagia and obesity [51].
Others found that catabolic changes in visceral fat depots due to
overexpression of uncoupling protein-1 (UCP1) lead to leptin-
dependent hypophagia, which can be abolished by vagal deaf-
ferentation [52]. Increased energy expenditure by CB1R blockade also
involves increased UCP1 expression in white adipocytes [53], and
vagal deafferentation was found to abolish the hypophagic effect of
rimonabant [54]. Taken together, these ﬁndings could suggest that an
interaction between endocannabinoids and leptin at the level of vagal
sensory afferents plays a role in the resensitization of hypothalamic
leptin signaling by peripheral CB1R blockade. Studies are in progress to
explore this intriguing possibility.
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Supplementary Figure 1. Leptin treatment counteracts the body weight reducing 
effect of peripheral CB1R blockade. (A) Body weight in wild-type mice on HFD, 
treated for 28 days with vehicle (n=8), with JD-5037 alone (1 mg/kg/day, i.p., n=4), or 
with JD5037 + leptin (3 mg/kg/day. i.p.), leptin being started on day 14 (n=4). Both 
HFD+JD5037 and HFD+JD5037+leptin are significantly different from HFD+vehicle 
from day 7 onwards (P<0.05 or less; two-way ANOVA with Tukey’s post-hoc test). 
*P<0.05 and #P<0.01 indicate significant difference between HFD+JD5037 vs. 
HFD+JD5037+leptin groups. (B) Serum leptin levels on day 26 in the 3 treatment 
groups. *P<0.05 vs. HFD+vehicle, n=4 in all 3 groups. 
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Supplementary Figure 2. NPY deletion does not affect the reduction in body 
weight and visceral fat mass by JD5037 treatment in DIO mice.  (A) Normalized 
body weights obtained from data shown in Figure 5A. Significance and number of 
observations are as in Figure 5A. (B) Weight of epididymal fat pads in STD and HFD-
fed WT and NPY-/- mice treated with vehicle or JD-5037 for 7 days. *P<0.0001 vs. 
STD and #P<0.05 vs. HFD vehicle treated; number of observations are as in Figure 5A. 
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Supplementary Figure 3. Peripheral CB1R blockade alters hypothalamic AEA, 
but not 2-AG levels, in DIO mice. C57Bl/6J male mice were fed STD or HFD for 14 
weeks, and then treated with JD5037 (3 mg/kg, po) for 2 days. 12 h following the last 
dose of JD5037, brain and hypothalamic 2-AG (A) and AEA (B) levels were 
determined by LC-MS/MS as described in the Methods. Note, an increased 
hypothalamic 2-AG levels in DIO mice, and normalization of hypothalamic AEA levels 
by JD5037 treatment. *P<0.05 vs. STD or HFD as indicated in the figure. Data are 
mean ± SEM from 5 animals per group.  
 
 
 
